CommercialPrior AuthHigh impact
Genetic Testing Update Effective July 1, 2026
Blue Cross Blue Shield of Nebraska·NE · Oncology, Genetics, Cardiology +1 more·Medical Policy
Effective date
Jul 1, 2026
We identified it
Jun 24, 2026
Summary
Blue Cross and Blue Shield of Nebraska is updating genetic testing policies effective July 1, 2026, adding new prior authorization requirements for oncology testing and specialty genetic conditions. Multiple new policies for ctDNA testing, NTRK fusion analysis, chromosomal microarray analysis, and cardiac troponin testing will require preauthorization.
Action Required
By July 1, 2026: Billing team must update prior authorization workflows for all genetic testing and oncology molecular diagnostics for Blue Cross Blue Shield of Nebraska members. Update billing system to flag preauthorization requirements for ctDNA testing for bladder and colorectal cancer, NTRK fusion analysis, PIK3CA variant analysis, chromosomal microarray analysis, and cardiac troponin tests. Train staff on new medical necessity criteria for each test type. Failure to obtain prior auth will result in claim denials.